timezone icon TimeZone (Europe/London)
file
过滤工艺
Reducing risk and decreasing timelines for biopharmaceutical cell line development through optimized reagents and processes
Thursday, November 30, 2017 04:00:00 PM GMT
Join us to learn about challenges faced with traditional expression systems and how a CHO cell line with the glutamine synthethase knock-out via  ZFN provides benefits for fast, efficient cell line development with stable and high titer expression.  

CHO cells with their unique characteristics, represent the major expression system within the biopharmaceutical industry. However, one of the major challenges in cell line development is to identify those rare, high-producing clones in a huge population of non-expressing or low-expressing cell lines. This leads to laborious and time consuming cell line development processes. This webinar will educate the audience about challenges faced with traditional expression systems and how the CHO cell line with the glutamine synthethase knock-out via Zinc Finger Nucleases provides benefits for fast and efficient cell line development as well as stable and high titer expression.  We will explore additional cell line engineering targets that can be modified to engineer a cell line that mitigates risks and removes bottlenecks throughout the biopharmaceutical process.
 
In this webinar, you will learn:
• What are the benefits of using an optimized/engineered expression system?
• What can be done throughout the cell line development process to mitigate risks and remove bottlenecks?
• Applications of cell line engineering for further upstream biopharmaceutical enhancements.

Speaker

Kate Achtien
Senior R&D Scientist

The vibrant M, Millipore, Milli-Q, Sigma-Aldrich, SAFC, Bioreliance and Supelco are trademarks of 
Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. 
Detailed information on trademarks is available via publicly accessible resources. 
© 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved.